Novartis AG
NVS
$147.85
$4.913.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.20% | 8.38% | 11.86% | 12.02% | 11.30% |
| Total Other Revenue | 44.30% | 52.46% | 49.52% | 46.35% | 18.94% |
| Total Revenue | 6.31% | 9.57% | 12.88% | 12.95% | 11.50% |
| Cost of Revenue | 6.86% | 6.31% | 10.93% | 9.50% | 6.77% |
| Gross Profit | 6.13% | 10.65% | 13.50% | 14.06% | 13.11% |
| SG&A Expenses | 4.19% | 5.37% | 6.58% | 5.58% | 2.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -27.14% | 0.58% | -160.11% | -66.52% | 44.01% |
| Total Operating Expenses | 8.31% | 7.51% | 10.47% | 6.87% | 5.60% |
| Operating Income | 2.25% | 14.06% | 17.52% | 26.53% | 25.66% |
| Income Before Tax | 5.81% | 19.88% | 28.96% | 43.21% | 53.29% |
| Income Tax Expenses | 10.30% | 40.21% | 108.82% | 142.01% | 230.87% |
| Earnings from Continuing Operations | 5.09% | 16.99% | 22.34% | 35.23% | 41.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2,100.00% | 750.00% | 150.00% | 900.00% | 66.67% |
| Net Income | 5.25% | 17.11% | -18.24% | -15.59% | -15.65% |
| EBIT | 2.25% | 14.06% | 17.52% | 26.53% | 25.66% |
| EBITDA | 2.56% | 11.72% | 14.63% | 19.88% | 17.75% |
| EPS Basic | 9.24% | 21.82% | -14.70% | -12.56% | -13.28% |
| Normalized Basic EPS | 2.54% | 15.62% | 21.79% | 31.14% | 29.95% |
| EPS Diluted | 9.18% | 21.54% | -14.76% | -12.68% | -13.39% |
| Normalized Diluted EPS | 2.62% | 15.67% | 21.78% | 31.10% | 29.89% |
| Average Basic Shares Outstanding | -3.80% | -3.97% | -3.81% | -3.35% | -2.90% |
| Average Diluted Shares Outstanding | -3.86% | -4.00% | -3.80% | -3.30% | -2.83% |
| Dividend Per Share | 20.81% | 20.81% | -1.44% | -1.44% | -1.44% |
| Payout Ratio | 0.06% | -0.12% | 0.25% | 0.21% | 0.76% |